Exelixis, Inc. (NASDAQ:EXEL) Director Sells $948,957.66 in Stock

Exelixis, Inc. (NASDAQ:EXEL) Director George Poste sold 20,634 shares of the stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $45.99, for a total transaction of $948,957.66. Following the completion of the sale, the director now owns 169,020 shares of the company’s stock, valued at approximately $7,773,229.80. This trade represents a 10.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Exelixis Trading Down 1.9%

EXEL opened at $45.40 on Monday. The company has a 50 day moving average of $37.23 and a 200 day moving average of $35.84. The company has a market cap of $12.51 billion, a PE ratio of 25.65, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $48.85.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Coppell Advisory Solutions LLC bought a new position in Exelixis in the 4th quarter valued at $25,000. Hemington Wealth Management boosted its holdings in Exelixis by 211.3% in the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 522 shares during the period. Colonial Trust Co SC boosted its holdings in Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 765 shares during the period. Principal Securities Inc. boosted its holdings in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 373 shares during the period. Finally, USA Financial Formulas bought a new position in Exelixis in the 4th quarter valued at $32,000. 85.27% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on EXEL. Oppenheimer lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $41.00 to $33.00 in a research note on Friday, January 24th. Stifel Nicolaus raised their price target on shares of Exelixis from $36.00 to $38.00 and gave the stock a “hold” rating in a research note on Wednesday, May 14th. Morgan Stanley restated an “overweight” rating and set a $47.00 price target (up previously from $40.00) on shares of Exelixis in a research note on Wednesday. StockNews.com lowered shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Finally, UBS Group restated an “underperform” rating on shares of Exelixis in a research note on Thursday, April 17th. Two analysts have rated the stock with a sell rating, six have given a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $38.76.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.